Poznan University of Medical Sciences
Poznan, Poznań, 61-701, Poland
NCT Number: NCT06304298
Effect of iPACK block on NLR and PLR following knee arthroplasty
Looking for future studies?
Notify Me20 year–90 year
All sexes
Interventional
Phase 4
Poznan, Poznań, 61-701, Poland
The NLR is a sensitive indicator of inflammation confirmed in numerous studies and has a predictive and prognostic value. NLR is a cheap, simple, fast-acting, readily available stress and inflammation parameter with high sensitivity and low specificity. Dynamic changes in the NLR precede the clinical state for several hours and may alert clinicians early about the ongoing pathological process. NLR is a new promising marker of cellular immune activation, an important indicator of stress and systemic inflammation. It opens a new dimension for clinical medicine to understand better the biology of inflammation, the linkage, and antagonism between innate and adaptive immunity, and its clinical consequences for health and disease.
NLR is affected not only by surgical trauma but also by the method of anesthesia. In recent years, the influence of regional anesthesiology on reducing the inflammatory response after surgical procedures has been emphasized. However, there have been very few studies evaluating the effect of various methods of anesthesia on the NLR.
This is the first study to investigate the effect of regional anesthesia on the NLR and PLR in patients undergoing knee replacement surgery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
After spinal anesthesia, the ultrasound-guided iPACK block will be performed with 20ml of 0.9% sodium chloride
Other names: Placebo
After spinal anesthesia, the ultrasound-guided iPACK block will be performed with 20ml of 0.2% ropivacine
Other names: iPACK block
Time frame: 12 hours after surgery
Neutrophil to lymphocyte ratio (NLR) is used as a marker of subclinical inflammation. It is calculated by dividing the number of neutrophils by number of lymphocytes, usually from peripheral blood sample, but sometimes also from cells that infiltrate tissue, such as tumor.
Time frame: 12 hours after surgery
Platelet-to-lymphocyte ratio
Time frame: 24 hours after surgery
Platelet-to-lymphocyte ratio
Time frame: 48 hours after surgery
Platelet-to-lymphocyte ratio
Time frame: 24 hours after surgery
Neutrophile-to-lymphocyte ratio
Time frame: 48 hours after surgery
Neutrophile-to-lymphocyte ratio
Time frame: 48 hours after procedure
Time after surgery when the patient needs opiate for the first time
Time frame: 48 hours after surgery
Total opiate consumption after surgery
Time frame: 4 hours after surgery
NRS (Numerical Rating Scale)
Time frame: 8 hours after surgery
NRS (Numerical Rating Scale)
Time frame: 12 hours after surgery
NRS (Numerical Rating Scale)
Time frame: 18 hours after surgery
NRS (Numerical Rating Scale)
Time frame: 24 hours after surgery
NRS (Numerical Rating Scale)
Time frame: 36 hours after surgery
NRS (Numerical Rating Scale)
Time frame: 48 hours after surgery
NRS (Numerical Rating Scale)
Poznan University of Medical Sciences
Other
The Neutrophil-to-lymphocyte Ratio (NLR) and Platelet-to-lymphocyte Ratio (PLR) Levels Following IPACK Block in Knee Arthroplasty: a Randomized, Controlled Trial.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06084403
Arthritis, Joint Diseases
Bursa, Turkey (Türkiye)
View Trial DetailsNCT06086483
Agnosia, Arthritis
Poznan, Poznań, Poland
View Trial DetailsNCT05103527
Arthritis, Joint Diseases
New York, United States
View Trial DetailsNCT06203483
Arthritis, Joint Diseases
Bursa, Turkey (Türkiye)
View Trial Details